Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes
Open accessThe DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of treatment to prevent thrombotic complications of acute coronary syndromes and percutaneous coronary intervention. METHODS: To compare prasugrel, a new thienopyridine, with clopidogrel, we randomly assigned 13,608 patients with moderate-to-high-risk acute coronary syndromes with scheduled percutaneous coronary intervention to receive prasugrel (a 60-mg loading dose and a 10-mg daily maintenance dose) or clopidogrel (a 300-mg loading dose and a 75-mg daily maintenance dose), for 6 to 15 months. The primary efficacy end point was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The key safety end point was major bleeding. RESULTS: The primary efficacy end point occurred in 12.1% of patients receiving clopidogrel and 9.9% of patients receiving prasugrel (hazard ratio for prasugrel vs. clopidogrel, 0.81; 95% confidence interval [CI], 0.73 to 0.90; P<0.001). We also found significant reductions in the prasugrel group in the rates of myocardial infarction (9.7% for clopidogrel vs. 7.4% for prasugrel; P<0.001), urgent target-vessel revascularization (3.7% vs. 2.5%; P<0.001), and stent thrombosis (2.4% vs. 1.1%; P<0.001). Major bleeding was observed in 2.4% of patients receiving prasugrel and in 1.8% of patients receiving clopidogrel (hazard ratio, 1.32; 95% CI, 1.03 to 1.68; P=0.03). Also greater in the prasugrel group was the rate of life-threatening bleeding (1.4% vs. 0.9%; P=0.01), including nonfatal bleeding (1.1% vs. 0.9%; hazard ratio, 1.25; P=0.23) and fatal bleeding (0.4% vs. 0.1%; P=0.002). CONCLUSIONS: In patients with acute coronary syndromes with scheduled percutaneous coronary intervention, prasugrel therapy was associated with significantly reduced rates of ischemic events, including stent thrombosis, but with an increased risk of major bleeding, including fatal bleeding. Overall mortality did not differ significantly between treatment groups. (ClinicalTrials.gov number, NCT00097591 [ClinicalTrials.gov].)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In patients with ACS undergoing PCI, 12 months' DAPT with low-dose ASA and prasugrel or ticagrelor was superior to DAPT with clopidogrel in the diabetes sub-group of the respective RCTs, with a benefit-risk profile similar to the overall trial populations (Supplementary data online, Tables S12-13).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [310]
In the citing paper
“With prasugrel, the primary efficacy endpoint occurred in 9.9% of patients as compared with 12.1% receiving clopidogrel (HR 0.81, 95% CI 0.73-0.90;P , 0.001).The risk of major bleeding was increased with prasugrel.501”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“With ticagrelor given for 12 months the composite endpoint of death from vascular causes, myocardial infarction, or stroke occurred in 9.8% as compared with 11.7% of those receiving clopidogrel (HR 0.84, 95% CI 0.77-0.92;P , 0.001).No significant difference in rate of major bleeding was found.501 -503”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
In the citing paper
“In patients with ACS for whom an early invasive strategy is planned, dual antiplatelet therapy with a P2Y12 inhibitor (ticagrelor or prasugrel) added to aspirin was superior to clopidogrel and aspirin.”
From European Guidelines on cardiovascular disease prevention in clinical practice (version 2012) (2012) · cites this paper as [501]
Citations
Cites
Collaboration, A. T. (2002) · BMJ · doi:10.1136/bmj.324.7329.71 · Cited by 6,943
(2001) · New England Journal of Medicine · doi:10.1056/nejmoa010746 · Cited by 6,470
Antman, E. M., Cohen, M., Bernink, P. J. L. M., McCabe, C. H., Horacek, T., Papuchis, G., Mautner, B., Corbalan, R., Radley, D., & Braunwald, E. (2000) · JAMA · doi:10.1001/jama.284.7.835 · Cited by 3,242
Self-citationSteinhubl, S. R., Berger, P. B., Mann III, J. T., Fry, E. T. A., DeLago, A., Wilmer, C., Topol, E. J., & for the CREDO Investigators (2002) · JAMA · doi:10.1001/jama.288.19.2411 · Cited by 3,078
Diener, H.-C., Bogousslavsky, J., Brass, L. M., Cimminiello, C., Csiba, L., Kaste, M., Leys, D., Matias-Guiu, J., & Rupprecht, H.-J. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16721-4 · Cited by 2,275
WRITING COMMITTEE MEMBERS, Smith, S. C., Feldman, T. E., Hirshfeld, J. W., Jacobs, A. K., Kern, M. J., King, S. B., Morrison, D. A., O’Neill, W. W., Schaff, H. V., et al. (2006) · Circulation · doi:10.1161/circulationaha.105.170815 · Cited by 2,218
Self-citationSabatine, M. S., Cannon, C. P., Gibson, C. M., López-Sendón, J. L., Montalescot, G., Theroux, P., Claeys, M. J., Cools, F., Hill, K. A., Skene, A. M., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050522 · Cited by 1,924
Self-citation(2005) · The Lancet · doi:10.1016/s0140-6736(05)67660-x · Cited by 1,858
Guidelines for Percutaneous Coronary Interventions
Silber, S., Albertsson, P., Avilés, F. F., Camici, P. G., Colombo, A., Hamm, C., Jørgensen, E., Marco, J., Nordrehaug, J.-E., Ruzyllo, W., et al. (2005) · European Heart Journal · doi:10.1093/eurheartj/ehi138 · Cited by 1,609
Stent Thrombosis in Randomized Clinical Trials of Drug-Eluting Stents
Mauri, L., Hsieh, W.-H., Massaro, J. M., Ho, K. K. L., D'Agostino, R., & Cutlip, D. E. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa067731 · Cited by 1,441
Research works printed but not linked: 1
- Varenhorst C, 2007, Eur Heart J, 28, 189
Cited by
Items 201–300 of 1,004
Antman, E. M., Wiviott, S. D., Murphy, S. A., Voitk, J., Hasin, Y., Widimsky, P., Chandna, H., Macias, W., McCabe, C. H., & Braunwald, E. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.04.002 · Cited by 328
Self-citationAntiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement
SIBBING, D., SCHULZ, S., BRAUN, S., MORATH, T., STEGHERR, J., MEHILLI, J., SCHÖMIG, A., VON BECKERATH, N., & KASTRATI, A. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03709.x · Cited by 324
Coronary Artery Disease in Patients ≥80 Years of Age
Madhavan, M. V., Gersh, B. J., Alexander, K. P., Granger, C. B., & Stone, G. W. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.12.068 · Cited by 320
Coronary stents: historical development, current status and future directions
Iqbal, J., Gunn, J., & Serruys, P. W. (2013) · British Medical Bulletin · doi:10.1093/bmb/ldt009 · Cited by 319
2023 ESC Guidelines for the management of acute coronary syndromes
Byrne, R. A., Rossello, X., Coughlan, J. J., Barbato, E., Berry, C., Chieffo, A., Claeys, M. J., Dan, G.-A., Dweck, M. R., Galbraith, M., et al. (2024) · European Heart Journal: Acute Cardiovascular Care · doi:10.1093/ehjacc/zuad107 · Cited by 314
Gender differences in the effects of cardiovascular drugs
Tamargo, J., Rosano, G., Walther, T., Duarte, J., Niessner, A., Kaski, J., Ceconi, C., Drexel, H., Kjeldsen, K., Savarese, G., et al. (2017) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw042 · Cited by 317
Chew, D. P., Scott, I. A., Cullen, L., French, J. K., Briffa, T. G., Tideman, P. A., Woodruffe, S., Kerr, A., Branagan, M., & Aylward, P. E. G. (2016) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2016.06.789 · Cited by 314
Cavallari, L. H., Lee, C. R., Beitelshees, A. L., Cooper-DeHoff, R. M., Duarte, J. D., Voora, D., Kimmel, S. E., McDonough, C. W., Gong, Y., Dave, C. V., et al. (2018) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.07.022 · Cited by 313
“Beitels Prasugrel and ticagrelor are alternative P2Y12 inhibitors, shown to be superior to clopidogrel in preventing cardiovascular events in patients with acute coronary syndrome (ACS) in the TRITON–TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thromboly…”
BackgroundAdenosine-Mediated Effects of Ticagrelor
Cattaneo, M., Schulz, R., & Nylander, S. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.031 · Cited by 312
“Prasugrel was also superior to clopidogrel in preventing the same composite endpoint in patients with ACS who underwent PCI in the TRITON trial (4).”
BackgroundMethodInfluentialPerk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, W. M. M., Albus, C., Benlian, P., Boysen, G., Cifkova, R., et al. (2012) · International Journal of Behavioral Medicine · doi:10.1007/s12529-012-9242-5 · Cited by 311
“No significant difference in rate of major bleeding was found.(501) With prasugrel, the primary efficacy endpoint occurred in 9.”
Sex and gender in cardiovascular medicine: presentation and outcomes of acute coronary syndrome
Haider, A., Bengs, S., Luu, J., Osto, E., Siller-Matula, J. M., Muka, T., & Gebhard, C. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz898 · Cited by 305
Levine, G. N., Bates, E. R., Bittl, J. A., Brindis, R. G., Fihn, S. D., Fleisher, L. A., Granger, C. B., Lange, R. A., Mack, M. J., Mauri, L., et al. (2016) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2016.07.044 · Cited by 304
“B-R Prasugrel should not be administered to patients with a prior history of stroke or TIA (54). systematic review.”
BackgroundMethodInfluentialHuber, K., Andreotti, F., Arnesen, H., Airaksinen, K. J., Cuisset, T., Kirchhof, P., Marín, F., & Lip, G. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-08-0580 · Cited by 303
Angiolillo, D. J., Bhatt, D. L., Cannon, C. P., Eikelboom, J. W., Gibson, C. M., Goodman, S. G., Granger, C. B., Holmes, D. R., Lopes, R. D., Mehran, R., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050438 · Cited by 302
Self-citationFranklin, J. M., Patorno, E., Desai, R. J., Glynn, R. J., Martin, D., Quinto, K., Pawar, A., Bessette, L. G., Lee, H., Garry, E. M., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.051718 · Cited by 299
Antiplatelet therapy after percutaneous coronary intervention
Angiolillo, D. A., Galli, M., Collet, J.-P., Kastrati, A., & O'Donoghue, M. O. (2022) · EuroIntervention · doi:10.4244/eij-d-21-00904 · Cited by 299
Veitch, A. M., Vanbiervliet, G., Gershlick, A. H., Boustiere, C., Baglin, T. P., Smith, L.-A., Radaelli, F., Knight, E., Gralnek, I. M., Hassan, C., et al. (2016) · Gut · doi:10.1136/gutjnl-2015-311110 · Cited by 296
Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
Erlinge, D., Omerovic, E., Fröbert, O., Linder, R., Danielewicz, M., Hamid, M., Swahn, E., Henareh, L., Wagner, H., Hårdhammar, P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706443 · Cited by 301
Mehta, S. K., Frutkin, A. D., Lindsey, J. B., House, J. A., Spertus, J. A., Rao, S. V., Ou, F.-S., Roe, M. T., Peterson, E. D., & Marso, S. P. (2009) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.108.846741 · Cited by 299
P2 receptors, platelet function and pharmacological implications
Gachet, C. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-11-0673 · Cited by 297
“A large scale clinical trial, TRITON-TIMI 38, including 13,609 patients planned for percutaneous coronary intervention (PCI) upon assessment of coronary anatomy, 3/4 with unstable angina, 1/4 with myocardial infarction, has demonstrated the overall superiority of prasugrel (60-mg loading dose followed by 10-mg mainten…”
BackgroundBecker, R. C., Moliterno, D. J., Jennings, L. K., Pieper, K. S., Pei, J., Niederman, A., Ziada, K. M., Berman, G., Strony, J., Joseph, D., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60230-0 · Cited by 299
Escaned, J., Collet, C., Ryan, N., Luigi De Maria, G., Walsh, S., Sabate, M., Davies, J., Lesiak, M., Moreno, R., Cruz-Gonzalez, I., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx512 · Cited by 294
Ferraris, V. A., Saha, S. P., Oestreich, J. H., Song, H. K., Rosengart, T., Reece, T. B., Mazer, C. D., Bridges, C. R., Despotis, G. J., Jointer, K., et al. (2012) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2012.07.086 · Cited by 293
“Prasugrel demonstrates more efficient generation of its active metabolite, and therefore more potent platelet inhibition; however, its improved efficacy is countered by an increase in bleeding, including fatal bleeding [17, 21, 22].”
BackgroundInfluentialKubica, J., Adamski, P., Ostrowska, M., Sikora, J., Kubica, J. M., Sroka, W. D., Stankowska, K., Buszko, K., Navarese, E. P., Jilma, B., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv547 · Cited by 287
Mega, J. L., & Simon, T. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60243-4 · Cited by 284
Lee, C. W., Ahn, J.-M., Park, D.-W., Kang, S.-J., Lee, S.-W., Kim, Y.-H., Park, S.-W., Han, S., Lee, S.-G., Seong, I.-W., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.003303 · Cited by 284
Current and future antiplatelet therapies: emphasis on preserving haemostasis
McFadyen, J. D., Schaff, M., & Peter, K. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.206 · Cited by 281
Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome
Bonello, L., Laine, M., Kipson, N., Mancini, J., Helal, O., Fromonot, J., Gariboldi, V., Condo, J., Thuny, F., Frere, C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.09.067 · Cited by 283
Basic Principles of Platelet Biology and Clinical Implications
Angiolillo, D. J., Ueno, M., & Goto, S. (2010) · Circulation Journal · doi:10.1253/circj.cj-09-0982 · Cited by 276
Bonello, L., Camoin-Jau, L., Armero, S., Com, O., Arques, S., Burignat-Bonello, C., Giacomoni, M.-P., Bonello, R., Collet, F., Rossi, P., et al. (2009) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.08.048 · Cited by 276
Aradi, D., Storey, R. F., Komócsi, A., Trenk, D., Gulba, D., Kiss, R. G., Husted, S., Bonello, L., Sibbing, D., Collet, J.-P., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht375 · Cited by 274
“Consensus summary In patients with acute coronary syndrome undergoing PCI, prasugrel and ticagrelor should be the preferred choices over clopidogrel unless contraindicationsexist (Supplementarymaterialonline,TableS4).(1,3,63,69,70)”
Background2007 WRITING COMMITTEE MEMBERS, Anderson, J. L., Adams, C. D., Antman, E. M., Bridges, C. R., Califf, R. M., Casey, D. E., Chavey, W. E., Fesmire, F. M., Hochman, J. S., et al. (2013) · Circulation · doi:10.1161/cir.0b013e31828478ac · Cited by 272
Self-citationMahla, E., Suarez, T. A., Bliden, K. P., Rehak, P., Metzler, H., Sequeira, A. J., Cho, P., Sell, J., Fan, J., Antonino, M. J., et al. (2012) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.111.967208 · Cited by 273
Macle, L., Cairns, J., Leblanc, K., Tsang, T., Skanes, A., Cox, J. L., Healey, J. S., Bell, A., Pilote, L., Andrade, J. G., et al. (2016) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2016.07.591 · Cited by 272
Factors influencing haemorrhagic transformation in ischaemic stroke
Álvarez-Sabín, J., Maisterra, O., Santamarina, E., & Kase, C. S. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70055-3 · Cited by 270
Kaul, S., & Diamond, G. A. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.065 · Cited by 269
Bauer, T., Bouman, H. J., van Werkum, J. W., Ford, N. F., ten Berg, J. M., & Taubert, D. (2011) · BMJ · doi:10.1136/bmj.d4588 · Cited by 266
Valgimigli, M. (2008) · JAMA · doi:10.1001/jama.299.15.joc80026 · Cited by 267
“Time from study drug bolus to first balloon inflation, median (IQR), min 40 (25-60) 40 (27-60) 41 (25-60) 45 (25-60) .”
Sex Differences in Outcomes After STEMI: Effect Modification by Treatment Strategy and Age
Cenko, E., Yoon, J., Kedev, S., Stankovic, G., Vasiljevic, Z., Krljanac, G., Kalpak, O., Ricci, B., Milicic, D., Manfrini, O., et al. (2018) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2018.0514 · Cited by 264
Weitz, J. I., Hirsh, J., & Samama, M. M. (2008) · Chest · doi:10.1378/chest.08-0673 · Cited by 262
Antithrombotic Therapy for Atrial Fibrillation with Stable Coronary Disease
(2019) · New England Journal of Medicine · doi:10.1056/nejmc1914049 · Cited by 260
Michelson, A. D., Frelinger, A. L., Braunwald, E., Downey, W. E., Angiolillo, D. J., Xenopoulos, N. P., Jakubowski, J. A., Li, Y., Murphy, S. A., Qin, J., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp159 · Cited by 257
“The results of the TRITON-TIMI 38 platelet substudy support the hypothesis that greater inhibition of ADP-mediated platelet function, both early and late following PCI in ACS patients, led to the lower incidence of ischaemic events, both early and late, and the increase in bleeding, observed in the TRITON-TIMI 38 stud…”
MethodResultInfluentialSelf-citationJaffer, I. H., & Weitz, J. I. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.06.021 · Cited by 250
Jakubowski, J. A., Winters, K. J., Naganuma, H., & Wallentin, L. (2007) · Cardiovascular Drug Reviews · doi:10.1111/j.1527-3466.2007.00027.x · Cited by 250
“The results of TRITON-TIMI 38 have recently been published (Wiviott et al. 2007).”
BackgroundO'Connor, R. E., Brady, W., Brooks, S. C., Diercks, D., Egan, J., Ghaemmaghami, C., Menon, V., O'Neil, B. J., Travers, A. H., & Yannopoulos, D. (2010) · Circulation · doi:10.1161/circulationaha.110.971028 · Cited by 250
Methodology for the Development of Antithrombotic Therapy and Prevention of Thrombosis Guidelines
Guyatt, G. H., Norris, S. L., Schulman, S., Hirsh, J., Eckman, M. H., Akl, E. A., Crowther, M., Vandvik, P. O., Eikelboom, J. W., McDonagh, M. S., et al. (2012) · Chest · doi:10.1378/chest.11-2288 · Cited by 251
Platelet thrombin receptor antagonism and atherothrombosis
Angiolillo, D. J., Capodanno, D., & Goto, S. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehp504 · Cited by 251
“14 The clinical efficacy of clopidogrel has been shown both as single antiplatelet therapy in high-risk patients with various manifestations of atherosclerotic disease, 18 and in conjunction with aspirin in high-risk patients with ACS, including unstable angina, ST-segment elevation (STE) myocardial infarction (MI), an…”
BackgroundInfluentialDangas, G. D., Caixeta, A., Mehran, R., Parise, H., Lansky, A. J., Cristea, E., Brodie, B. R., Witzenbichler, B., Guagliumi, G., Peruga, J. Z., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.981688 · Cited by 248
2011 ACCF/AHA guideline for coronary artery bypass graft surgery: Executive summary
Hillis, L. D., Smith, P. K., Anderson, J. L., Bittl, J. A., Bridges, C. R., Byrne, J. G., Cigarroa, J. E., DiSesa, V. J., Hiratzka, L. F., Hutter, A. M., et al. (2012) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2011.10.015 · Cited by 248
Warner, T. D., Nylander, S., & Whatling, C. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2011.03943.x · Cited by 245
Ungerer, M., Rosport, K., Bültmann, A., Piechatzek, R., Uhland, K., Schlieper, P., Gawaz, M., & Münch, G. (2011) · Circulation · doi:10.1161/circulationaha.110.980623 · Cited by 245
Galli, M., Benenati, S., Capodanno, D., Franchi, F., Rollini, F., D'Amario, D., Porto, I., & Angiolillo, D. J. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00533-x · Cited by 244
Thiele, H., Wöhrle, J., Hambrecht, R., Rittger, H., Birkemeyer, R., Lauer, B., Neuhaus, P., Brosteanu, O., Sick, P., Wiemer, M., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(11)61872-2 · Cited by 245
Platelet Signaling and Disease: Targeted Therapy for Thrombosis and Other Related Diseases
Yeung, J., Li, W., & Holinstat, M. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014530 · Cited by 242
“Importantly, anti-PAR4 antibodies did not significantly prolong bleed times in the guinea pig cuticleand renal-provoked bleeding time models (Wong et al., 2017).”
BackgroundInfluentialZhao, Q., Zhu, Y., Xu, Z., Cheng, Z., Mei, J., Chen, X., & Wang, X. (2018) · JAMA · doi:10.1001/jama.2018.3197 · Cited by 239
Andreotti, F., Rocca, B., Husted, S., Ajjan, R. A., ten Berg, J., Cattaneo, M., Collet, J.-P., De Caterina, R., Fox, K. A. A., Halvorsen, S., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv304 · Cited by 241
“is EMA/FDA-approved for age ≥75 years (IIa B)(58,59) Contraindicated if prior stroke/ TIA, including ICH (III B).(60)”
BackgroundInfluentialSelf-citationAbraham, N. S., Hlatky, M. A., Antman, E. M., Bhatt, D. L., Bjorkman, D. J., Clark, C. B., Furberg, C. D., Johnson, D. A., Kahi, C. J., Laine, L., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.09.010 · Cited by 239
Self-citationAntiplatelet agents for the treatment and prevention of atherothrombosis
Patrono, C., Andreotti, F., Arnesen, H., Badimon, L., Baigent, C., Collet, J.-P., De Caterina, R., Gulba, D., Huber, K., Husted, S., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr373 · Cited by 243
Self-citationAngiolillo, D. J., Goodman, S. G., Bhatt, D. L., Eikelboom, J. W., Price, M. J., Moliterno, D. J., Cannon, C. P., Tanguay, J.-F., Granger, C. B., Mauri, L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034722 · Cited by 238
Self-citationSarafoff, N., Martischnig, A., Wealer, J., Mayer, K., Mehilli, J., Sibbing, D., & Kastrati, A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.036 · Cited by 236
“As it is known that the second generation thienopyridine prasugrel as compared to clopidogrel is associated with higher bleeding rates (15), it is felt, that its routine use in patients with triple therapy is not recommended.”
BackgroundDe Luca, G., Dirksen, M. T., Spaulding, C., Kelbæk, H., Schalij, M., Thuesen, L., van der Hoeven, B., Vink, M. A., Kaiser, C., Musto, C., et al. (2012) · Archives of Internal Medicine · doi:10.1001/archinternmed.2012.758 · Cited by 235
The Task Force on diabetes, P.-D. (2014) · Diabetes and Vascular Disease Research · doi:10.1177/1479164114525548 · Cited by 236
Schulz, S., Schuster, T., Mehilli, J., Byrne, R. A., Ellert, J., Massberg, S., Goedel, J., Bruskina, O., Ulm, K., Schomig, A., et al. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp275 · Cited by 234
Kuliczkowski, W., Witkowski, A., Polonski, L., Watala, C., Filipiak, K., Budaj, A., Golanski, J., Sitkiewicz, D., Pregowski, J., Gorski, J., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn562 · Cited by 233
Berger, P. B., Bhatt, D. L., Fuster, V., Steg, P. G., Fox, K. A. A., Shao, M., Brennan, D. M., Hacke, W., Montalescot, G., Steinhubl, S. R., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.895342 · Cited by 231
Self-citationHusted, S., James, S., Becker, R. C., Horrow, J., Katus, H., Storey, R. F., Cannon, C. P., Heras, M., Lopes, R. D., Morais, J., et al. (2012) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.111.964395 · Cited by 232
Outcomes With Concurrent Use of Clopidogrel and Proton-Pump Inhibitors: A Cohort Study
Ray, W. A., Murray, K. T., Griffin, M. R., Chung, C. P., Smalley, W. E., Hall, K., Daugherty, J. R., Kaltenbach, L. A., & Stein, C. M. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-6-201003160-00003 · Cited by 230
Lip, G. Y. H., Huber, K., Andreotti, F., Arnesen, H., Airaksinen, J. K., Cuisset, T., Kirchhof, P., & Marin, F. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq117 · Cited by 229
Forman, D. E., Rich, M. W., Alexander, K. P., Zieman, S., Maurer, M. S., Najjar, S. S., Cleveland, J. C., Krumholz, H. M., & Wenger, N. K. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.02.014 · Cited by 228
“anced by increased bleeding risks in older patients (32).”
Clopidogrel Pharmacogenetics: State-of-the-Art Review and the TAILOR-PCI Study
Pereira, N. L., Rihal, C. S., So, D. Y. F., Rosenberg, Y., Lennon, R. J., Mathew, V., Goodman, S. G., Weinshilboum, R. M., Wang, L., Baudhuin, L. M., et al. (2019) · Circulation: Cardiovascular Interventions · doi:10.1161/circinterventions.119.007811 · Cited by 227
Evidence Review Committee Members, Bittl, J. A., Baber, U., Bradley, S. M., & Wijeysundera, D. N. (2016) · Circulation · doi:10.1161/cir.0000000000000405 · Cited by 227
Hansson, E. C., Jidéus, L., Åberg, B., Bjursten, H., Dreifaldt, M., Holmgren, A., Ivert, T., Nozohoor, S., Barbu, M., Svedjeholm, R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv381 · Cited by 226
“more potent platelet inhibitors, ticagrelor or prasugrel, is used instead of clopidogrel,(2,3) but the risk of both spontaneous and surgical bleeding complications may increase with the new inhibitors.(3,4) Major bleeding complications impair outcome after cardiac surgery.”
BackgroundWriting Committee Members, Holmes, D. R., Dehmer, G. J., Kaul, S., Leifer, D., O'Gara, P. T., & Stein, C. M. (2010) · Circulation · doi:10.1161/cir.0b013e3181ee08ed · Cited by 223
Kulik, A., Le May, M. R., Voisine, P., Tardif, J.-C., DeLarochelliere, R., Naidoo, S., Wells, G. A., Mesana, T. G., & Ruel, M. (2010) · Circulation · doi:10.1161/circulationaha.110.978007 · Cited by 221
Ohman, E. M., Roe, M. T., Steg, P. G., James, S. K., Povsic, T. J., White, J., Rockhold, F., Plotnikov, A., Mundl, H., Strony, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30751-1 · Cited by 223
Self-citationVeitch, A., Vanbiervliet, G., Gershlick, A., Boustiere, C., Baglin, T., Smith, L.-A., Radaelli, F., Knight, E., Gralnek, I., Hassan, C., et al. (2016) · Endoscopy · doi:10.1055/s-0042-102652 · Cited by 226
Morphine Decreases Clopidogrel Concentrations and Effects
Hobl, E.-L., Stimpfl, T., Ebner, J., Schoergenhofer, C., Derhaschnig, U., Sunder-Plassmann, R., Jilma-Stohlawetz, P., Mannhalter, C., Posch, M., & Jilma, B. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.10.068 · Cited by 222
Angiolillo, D. J., Bernardo, E., Capodanno, D., Vivas, D., Sabaté, M., Ferreiro, J. L., Ueno, M., Jimenez-Quevedo, P., Alfonso, F., Bass, T. A., et al. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.10.043 · Cited by 220
Cattaneo, M. (2010) · Circulation · doi:10.1161/circulationaha.109.853069 · Cited by 220
Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis
Patrono, C., Morais, J., Baigent, C., Collet, J.-P., Fitzgerald, D., Halvorsen, S., Rocca, B., Siegbahn, A., Storey, R. F., & Vilahur, G. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.08.037 · Cited by 221
Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) Guideline
Boustière, C., Veitch, A., Vanbiervliet, G., Bulois, P., Deprez, P., Laquiere, A., Laugier, R., Lesur, G., Mosler, P., Nalet, B., et al. (2011) · Endoscopy · doi:10.1055/s-0030-1256317 · Cited by 218
“…clotting, it can be calculated that the minimal durations of APA discontinuation that allow for restoration of normal platelet aggregability are 5 days for aspirin/clopidogrel and 7 days for prasugrel (based on the prolonged and more effective action of prasugrel compared with clopidogrel) [8].”
Scirica, B. M., Bonaca, M. P., Braunwald, E., De Ferrari, G. M., Isaza, D., Lewis, B. S., Mehrhof, F., Merlini, P. A., Murphy, S. A., Sabatine, M. S., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61269-0 · Cited by 217
Self-citationBhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.529 · Cited by 216
Self-citationPalmerini, T., Biondi-Zoccai, G., Della Riva, D., Mariani, A., Sabaté, M., Valgimigli, M., Frati, G., Kedhi, E., Smits, P. C., Kaiser, C., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.022 · Cited by 215
“This hypothesis is consistent with the findings of the TRITONTIMI 38 trial in which a 50% reduction in the 30-day rate of STwith prasugrel compared to clopidogrel was associatedwith a significant reduction in the risk of 30-day cardiac death/MI (24).”
ResultErlinge, D., Varenhorst, C., Braun, O. Ö., James, S., Winters, K. J., Jakubowski, J. A., Brandt, J. T., Sugidachi, A., Siegbahn, A., & Wallentin, L. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.07.068 · Cited by 215
Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention
Capodanno, D., Mehran, R., Valgimigli, M., Baber, U., Windecker, S., Vranckx, P., Dangas, G., Rollini, F., Kimura, T., Collet, J.-P., et al. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0049-1 · Cited by 214
Self-citationKim, C. J., Park, M.-W., Kim, M. C., Choo, E.-H., Hwang, B.-H., Lee, K. Y., Choi, Y. S., Kim, H.-Y., Yoo, K.-D., Jeon, D.-S., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01445-8 · Cited by 214
Restenosis, Stent Thrombosis, and Bleeding Complications
Torrado, J., Buckley, L., Durán, A., Trujillo, P., Toldo, S., Valle Raleigh, J., Abbate, A., Biondi-Zoccai, G., & Guzmán, L. A. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.023 · Cited by 212
“The story of 40 years of PCI can be illustrated as Odysseus’s ship navigating through a strait, in which 2 “sea hazards” are situated close enough to each other that they posed an unavoidable threat to passing sailors: avoiding Charybdis (e.g., restenosis) could mean passing too close to Scylla (e.g., thrombosis), as…”
BackgroundInfluentialMehta, S. R., Bainey, K. R., Cantor, W. J., Lordkipanidzé, M., Marquis-Gravel, G., Robinson, S. D., Sibbald, M., So, D. Y., Wong, G. C., Abunassar, J. G., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.012 · Cited by 211
Kim, H.-S., Kang, J., Hwang, D., Han, J.-K., Yang, H.-M., Kang, H.-J., Koo, B.-K., Rhew, J. Y., Chun, K.-J., Lim, Y.-H., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31791-8 · Cited by 209
Extracellular ATP and adenosine: The Yin and Yang in immune responses?
Faas, M. M., Sáez, T., & de Vos, P. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.01.002 · Cited by 208
Bonello, L., Pansieri, M., Mancini, J., Bonello, R., Maillard, L., Barnay, P., Rossi, P., Ait-Mokhtar, O., Jouve, B., Collet, F., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.04.017 · Cited by 209
Lindholm, D., Varenhorst, C., Cannon, C. P., Harrington, R. A., Himmelmann, A., Maya, J., Husted, S., Steg, P. G., Cornel, J. H., Storey, R. F., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu160 · Cited by 208
Claessen, B. E., Henriques, J. P. S., Jaffer, F. A., Mehran, R., Piek, J. J., & Dangas, G. D. (2014) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2014.05.016 · Cited by 207
Rutter, M. D., Chattree, A., Barbour, J. A., Thomas-Gibson, S., Bhandari, P., Saunders, B. P., Veitch, A. M., Anderson, J., Rembacken, B. J., Loughrey, M. B., et al. (2015) · Gut · doi:10.1136/gutjnl-2015-309576 · Cited by 206
Eikelboom, J., Berger, P., Holmes, D., Bhatt, D., Becker, R., Angiolill, D., Faxon, D., & Moliterno, D. (2011) · Thrombosis and Haemostasis · doi:10.1160/th11-04-0262 · Cited by 204
“Prasugrel has been shown to cause more intracranial bleeding than clopidogrel in patients with prior cerebrovascular disease, and elevated mortality rates have been reported following intracranial haemorrhage among patients treated with ticagrelor (49, 50).”
BackgroundAntiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period
Hall, R., & Mazer, C. D. (2011) · Anesthesia & Analgesia · doi:10.1213/ane.0b013e318203f38d · Cited by 203
“32).(172) There was a higher incidence of life-threatening bleeding (1.”
BackgroundMethodMotovska, Z., Hlinomaz, O., Miklik, R., Hromadka, M., Varvarovsky, I., Dusek, J., Knot, J., Jarkovsky, J., Kala, P., Rokyta, R., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.024823 · Cited by 203
Mortality Benefit With Prasugrel in the TRITON–TIMI 38 Coronary Artery Bypass Grafting Cohort
Smith, P. K., Goodnough, L. T., Levy, J. H., Poston, R. S., Short, M. A., Weerakkody, G. J., & LeNarz, L. A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.03.030 · Cited by 203
“001) when adjudicated by using the TIMI criteria (6).”
InfluentialSelf-citation
Metadata
- Authors
- Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F.-J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., & Antman, E. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Inserm (FR)
- Bikur Cholim Hospital (IL)
- Universitäts-Herzzentrum Freiburg-Bad Krozingen (DE)
- Ospedale di Parma (IT)
- Eli Lilly (United States) (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-11-15
- Volume
- 357
- Issue
- 20
- Pages
- 2001-2015
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2169387542
- Cited by
- 6,790
- References
- 40
- Citations by year
- 2026: 162 · 2025: 202 · 2024: 187 · 2023: 265 · 2022: 309 · 2021: 326 · 2020: 339 · 2019: 361 · 2018: 389 · 2017: 418 · 2016: 419 · 2015: 465 · 2014: 448 · 2013: 502 · 2012: 507
- FWCI
- 238.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Keywords
- prasugrel, clopidogrel, acute coronary syndrome, percutaneous coronary intervention, dual antiplatelet therapy, thienopyridines, major bleeding, stent thrombosis, myocardial infarction, target vessel revascularization, cardiovascular mortality, bleeding risk stratification, bleeding risk score
- MeSH terms
- Prasugrel Hydrochloride, Clopidogrel, Aged, Aspirin, Double-Blind Method, Drug Therapy, Combination, Female, Hemorrhage, Humans, Male, Middle Aged, Myocardial Infarction, Piperazines, Platelet Aggregation Inhibitors, Prodrugs, Thiophenes, Thrombosis, Ticlopidine, Angioplasty, Balloon, Coronary, Stroke, Kaplan-Meier Estimate, Acute Coronary Syndrome, Purinergic P2 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.